AXON Neuroscience

14 articles about AXON Neuroscience

• 

  Alzheimer’s Vaccine Could Be on the Horizon

  10/27/2021

  Nuravax is developing an Alzheimer's vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins. Know more here.

• AXON Neuroscience to Present New Results from Phase II Clinical Study at 2021 Alzheimer's Association International Conference

  7/27/2021

  AXON NEUROSCIENCE SE announced it will present new results from its Phase II clinical study of its tau vaccine AADvac1 against Alzheimer's disease at the 2021 Alzheimer's Association International Conference, which is being held in Denver, Colorado and virtually, 26th - 30th July.

• Axon Neuroscience to Present at 2021 BIO Digital

  6/10/2021

  Axon Neuroscience to present its 2nd generation COVID-19 monoclonal antibody ACmab1 at the premier biotech event.

• Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development

  4/9/2020

  AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases, is developing a promising vaccine candidate against COVID-19.     Axon has over 20 years' experience in development of safe and immunogenic peptide vaccines. Its well-established

• 

  Clinical Catch-Up: March 30 – April 3

  4/6/2020

  This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.

• Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

  4/3/2020

  AADvac1 has a disease-modifying effect on Alzheimer's Disease, evidenced by a combination of several biomarkers and clinical outcomes, most pronounced among younger patients;

• 

  Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study

  4/3/2020

  During a presentation at the AAT-AD/PD 2020 conference, Axon said AADvac1 showed a disease-modifying effect on Alzheimer's disease.

• Axon Announces Positive Results From Phase II ADAMANT Trial for AADvac1 in Alzheimer's Disease

  9/9/2019

  AXON Neuroscience SE has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer's Disease.

• Axon Neuroscience Appoints Michal Fresser as Group CEO

  8/1/2019

  AXON NEUROSCIENCE SE announces the appointment of Michal Fresser as Chief Executive Officer of Axon Group.

• AXON Neuroscience's Tau Vaccine Has Completed Phase II Enrolment In Alzheimer's

  7/17/2017

• AXON Neuroscience's Tau Vaccine Offers Potential For Treating Frontotemporal Dementia Patients

  4/3/2017

• AXON Neuroscience’s Alzheimer Tau Vaccine Phase 1 Study Results Published In Lancet Neurology

  12/12/2016

• AXON Neuroscience’s Pioneering Tau Vaccine Against Alzheimer's Started Phase II

  6/22/2016

• AXON Neuroscience Presented Its Tau Vaccine In Two Presentations At 14Th AAT Conference

  3/18/2016